Publications
Recent high-impact publications from Rogel Cancer Center members.
|
|
Publications from members of the Cancer Biology, Cancer Genetics, Cancer Hematopoiesis & Immunology, and Developmental Therapeutics programs |
|
Kitamoto, S.; Nagao-Kitamoto, H.; Jiao, Y.; Gillilland, M. G. 3rd; Hayashi, A.; Imai, J.; Sugihara, K.; Miyoshi, M.; Brazil, J. C.; Kuffa, P.; Hill, B. D.; Rizvi, S. M.; Wen, F.; Bishu, S.; Inohara, N.; Eaton, K. A.; Nusrat, A.; Lei, Y. L.; Giannobile, W. V.; Kamada, N. The Intermucosal Connection between the Mouth and Gut in Commensal Pathobiont-Driven Colitis. Cell (2020) 182:447-462.e14. PMID: 32758418. PMCID: PMC7414097.
Guan, X.; Sun, D.; Lu, E.; Urrutia, J. A.; Reiter, R. E.; Rettig, M.; Evans, C. P.; Lara, P. Jr; Gleave, M.; Beer, T. M.; Thomas, G. V.; Huang, J.; Aggarwal, R. R.; Quigley, D. A.; Foye, A.; Chen, W. S.; Youngren, J.; Weinstein, A. S.; Stuart, J. M.; Feng, F. Y.; Small, E. J.; Xia, Z.; Alumkal, J. J. Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res (2020) PMID: 32727885. PMCID: PMC7484240.
Aggarwal, R. R.; Schweizer, M. T.; Nanus, D. M.; Pantuck, A. J.; Heath, E. I.; Campeau, E.; Attwell, S.; Norek, K.; Snyder, M.; Bauman, L.; Lakhotia, S.; Feng, F. Y.; Small, E. J.; Abida, W.; Alumkal, J. J. A Phase 1b/2a Study of the Pan-BET Bromodomain Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer. Clin Cancer Res (2020) PMID: 32694156. PMCID: PMC7572827.
Huang, H.; Howard, C. A.; Zari, S.; Cho, H. J.; Shukla, S.; Li, H.; Ndoj, J.; Gonzalez-Alonso, P.; Nikolaidis, C.; Abbott, J.; Rogawski, D. S.; Potopnyk, M. A.; Kempinska, K.; Miao, H.; Purohit, T.; Henderson, A.; Mapp, A.; Sulis, M. L.; Ferrando, A.; Grembecka, J.; Cierpicki, T. Covalent Inhibition of NSD1 Histone Methyltransferase. Nat Chem Biol (2020) PMID: 32868895. PMCID: PMC7669657.
Hassani Najafabadi, A.; Zhang, J.; Aikins, M. E.; Najaf Abadi, Z. I.; Liao, F.; Qin, Y.; Okeke, E. B.; Scheetz, L. M.; Nam, J.; Xu, Y.; Adams, D.; Lester, P.; Hetrick, T.; Schwendeman, A.; Wicha, M. S.; Chang, A. E.; Li, Q.; Moon, J. J. Cancer Immunotherapy via Targeting Cancer Stem Cells Using Vaccine Nanodiscs. Nano Lett (2020) PMID: 32926633. PMCID: PMC7572838.
Bian, Y.; Li, W.; Kremer, D. M.; Sajjakulnukit, P.; Li, S.; Crespo, J.; Nwosu, Z. C.; Zhang, L.; Czerwonka, A.; Pawlowska, A.; Xia, H.; Li, J.; Liao, P.; Yu, J.; Vatan, L.; Szeliga, W.; Wei, S.; Grove, S.; Liu, J. R.; McLean, K.; Cieslik, M.; Chinnaiyan, A. M.; Zgodzinski, W.; Wallner, G.; Wertel, I.; Okla, K.; Kryczek, I.; Lyssiotis, C. A.; Zou, W. Cancer SLC43A2 Alters T Cell Methionine Metabolism and Histone Methylation. Nature (2020) PMID: 32879489. PMCID: PMC7486248.
|
|
|
|
|
"That subset of patients with frontline resistance to enzalutamide or abiraterone and low androgen receptor activity are the ones who appeared to respond best to ZEN-3694 — suggesting a promising treatment approach for this group of patients whose cancers behave quite poorly with currently approved treatments." - Joshi Alumkal, M.D.
|
|
|
|
We want to hear your feedback!
|
|
Please forward this message to your colleagues.
|
|
|
|
|
|
|
